A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

Kyle LaHucik

Senior Reporter

Another relatively mysterious anti-aging biotech has emerged and the details are once again slim. Retro Biosciences said it has reeled in an initial pool of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A new an­ti-ag­ing biotech wants to add 10 years to your life. But who's fund­ing it?

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Will CRISPR mat­ter?

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A new anti-aging biotech wants to add 10 years to your life. But who's funding it?

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence